We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cervical Cancer Test Can Improve Early Detection

By LabMedica International staff writers
Posted on 05 Dec 2012
Immunological methods have been used to detect an oncoprotein associated with human papillomaviruses (HPV) that cause cervical cancer. More...


Immunological detection of the E7 oncoprotein is an attractive alternative for triage of suspicious and borderline cytology to highlight and identify the often-rare dysplastic cells present in a cell scrape.

Scientists at the University of Gothenburg (Sweden) raised monoclonal antibodies against the E7 oncoprotein, which is an absolute prerequisite of malignant transformation and the protein is expressed at increasing levels during cancer development.

Antibodies specific for the E7 protein of oncogenic HPV types were selected using immunological methods such as enzyme-linked immunosorbent assay (ELISA), Western blot, immunocytochemistry and flow cytometry. Phage display was used to identify antibody epitopes thereby predicting and verifying antibody specificity.

Two of the antibodies, recognizing HPV16 and HPV18 E7 demonstrated strong staining of dysplastic cells in HPV-positive specimens in immunocytochemistry and could have the potential to be used in a clinical setting. Since the antibodies detect the protein in Liquid-based cytology, which normally leaves residual sample after standard cytology, E7 testing can easily be performed without recalling the patient for additional sampling. About 250 women in Sweden still die every year due to cervical cancer, while another 500 develop the cancer, regardless of intensive screenings.

Maria Lidqvist, a doctoral student at the Sahlgrenska Academy (Gothenburg, Sweden) who presented this new technique in her thesis, said, “Around 70% of all cervical cancer cases are caused by two specific virus types, known as HPV16 and HPV18. We have developed a method that identifies proteins of these or oncogenic viruses in cells, enabling a more objective interpretation of the test results. Monoclonal antibodies against human papillomavirus E7 oncoprotein can be used for diagnosis of cervical neoplasia and cancer. This method can hopefully produce a more reliable diagnosis in uncertain cases and reduce the number of missed cancer cases, as well as the number of women who have to be recalled because of cell samples that are difficult to interpret.”

Related Links:
University of Gothenburg
Sahlgrenska Academy




New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.